


Biotechnology/Chemical Division
Scientific and Technical Information Center



Search Results Feedback Form

The results for your recent search request are attached. If you have any questions or comments about the scope or the results of the search, please contact the searcher whose name is stamped below.

Point of Contact:

Barb O'Bryen

Technical Info. Specialist

CM1 12C14 Tel: 308-4291

John Dantzman	308-4488	Jan Delaval	308-4498	Mary Hale	308-4258	Susan Hanley	305-4053
Edward Hart	305-9203	Barb O'Bryen	308-4291	Toby Port	308-3534	David Schreiber	308-4292
Beverly Shears	308-4994	Paula Sheppard	308-4499	Mona Smith	308-3278	Alex Waclawiw	308-4491

Compliment or Complaint, contact:

Stephanie Publicker
Information Branch Chief – STIC
Phone: 308-4740

Arti Shah
Division Chief – Biotech/Chem Division – STIC
Phone: 308-4259

=> fil reg; d stat que 18; fil capl; d que nos 19

FILE 'REGISTRY' ENTERED AT 15:59:09 ON 21 AUG 2000
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 20 AUG 2000 HIGHEST RN 286833-04-3
 DICTIONARY FILE UPDATES: 20 AUG 2000 HIGHEST RN 286833-04-3


TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
 for details.

L6

STR



```
VAR G1=C/N
VAR G2=2/3/4
REP G3=(0-1) O
VPA 20-8/9/10 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 14 23
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23
```

```
STEREO ATTRIBUTES: NONE
L8 172 SEA FILE=REGISTRY SSS FUL L6
```

```
100.0% PROCESSED 102627 ITERATIONS 172 ANSWERS
SEARCH TIME: 00.00.15
```

FILE 'CAPLUS' ENTERED AT 15:59:10 ON 21 AUG 2000
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 Searched by Barb O'Bryen, STIC 308-4291

COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 21 Aug 2000 VOL 133 ISS 9
FILE LAST UPDATED: 20 Aug 2000 (20000820/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

L6 STR
L8 172 SEA FILE=REGISTRY SSS FUL L6
L9 6 SEA FILE=CAPLUS ABB=ON L8

=> d ibib abs hitstr 19 1-6; fil cao; d que nos 110

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:282201 CAPLUS
DOCUMENT NUMBER: 130:311793
TITLE: Preparation of amides as antidiabetics
INVENTOR(S): Maruyama, Tatsuya; Suzuki, Takayuki; Onda, Kenichi; Hayakawa, Masahiko; Moritomo, Hiroyuki; Kimizuka, Tetsuya; Matsui, Tetsuo
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920607	A1	19990429	WO 1998-JP4671	19981015
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9889288	A1	19990506	AU 1998-89288	19981013
AU 9894621	A1	19990510	AU 1998-94621	19981015
EP 1028111	A1	20000816	EP 1998-947894	19981015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				



Searched by Barb O'Bryen, STIC 308-4291

Archived

CN 1218045	A 19990602	CN 1998-121375	19981016
NO 2000001983	A 20000414	NO 2000-1983	20000414
PRIORITY APPLN. INFO.:		JP 1997-285778	19971017
		WO 1998-JP4671	19981015

OTHER SOURCE(S): MARPAT 130:311793

GI



AB The title compds. I [ring B = an optionally substituted heteroaryl optionally fused with a benzene ring; X = a bond, lower alkylene or lower alkenylene (optionally substituted by hydroxy or lower alkyl), carbonyl, or NH (further details related to X are given); A = a lower alkylene or a group represented by (lower alkylene)-O; R1a and R1b = hydrogen or lower alkyl; R2 = hydrogen or halogeno; and Z = nitrogen or CH] are prepd. I are useful as diabetes remedies which not only function to accelerate the secretion of insulin and enhance insulin sensitivity but also have an anti-obesity action and an antihyperlipemic action based on their selective stimulative action on .beta.3 receptor. For example, imidazole deriv. II was prepd. Compds. of this invention significantly decreased blood sugar in mice.

IT 223672-09-1P 223672-10-4P 223672-11-5P
 223672-12-6P 223672-13-7P 223672-14-8P
 223672-15-9P 223672-16-0P 223672-17-1P
 223672-18-2P 223672-19-3P 223672-20-6P
 223672-21-7P 223672-22-8P 223672-23-9P
 223672-24-0P 223672-25-1P 223672-26-2P
 223672-27-3P 223672-29-5P 223672-30-8P
 223672-31-9P 223672-32-0P 223672-34-2P
 223672-36-4P 223672-38-6P 223672-40-0P
 223672-42-2P 223672-44-4P 223672-46-6P
 223672-47-7P 223672-48-8P 223672-49-9P
 223672-50-2P 223672-51-3P 223672-52-4P
 223672-53-5P 223672-55-7P 223672-58-0P
 223672-60-4P 223672-63-7P 223672-65-9P
 223672-66-0P 223672-67-1P 223672-68-2P
 223672-69-3P 223672-70-6P 223672-71-7P
 223672-72-8P 223672-73-9P 223672-74-0P
 223672-75-1P 223672-76-2P 223672-77-3P
 223672-78-4P 223672-79-5P 223672-80-8P

Searched by Barb O'Bryen, STIC 308-4291


223672-81-9P 223672-82-0P 223672-83-1P
 223672-84-2P 223672-85-3P 223672-86-4P
 223672-87-5P 223672-88-6P 223672-89-7P
 223672-90-0P 223672-91-1P 223672-92-2P
 223672-93-3P 223672-94-4P 223672-95-5P
 223672-96-6P 223672-97-7P 223672-98-8P
 223672-99-9P 223673-00-5P 223673-01-6P
 223673-02-7P 223673-03-8P 223673-04-9P
 223673-05-0P 223673-06-1P 223673-07-2P
 223673-08-3P 223673-09-4P 223673-10-7P
 223673-11-8P 223673-12-9P 223673-13-0P
 223673-14-1P 223673-15-2P 223673-16-3P
 223673-17-4P 223673-18-5P 223673-19-6P
 223673-20-9P 223673-21-0P 223673-22-1P
 223673-23-2P 223673-25-4P 223673-26-5P
 223673-27-6P 223673-28-7P 223673-29-8P
 223673-30-1P 223673-31-2P 223673-32-3P
 223673-33-4P 223673-58-3P 223673-59-4P
 223673-60-7P 223673-61-8P 223673-62-9P
 223673-63-0P 223673-64-1P 223673-65-2P
 223673-66-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of amides as antidiabetics)

RN 223672-09-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-10-4 CAPLUS

CN 8-Quinolinescarboxamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-11-5 CAPLUS

CN 2-Propenamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-3-(2-pyridinyl)-, dihydrochloride, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




● 2 HCl

RN 223672-12-6 CAPLUS

CN 2-Benzothiazoleacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-13-7 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291

CN Imidazo[2,1-b]thiazole-5-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-14-8 CAPLUS

CN 4-Thiazoleacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-15-9 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-16-0 CAPLUS

CN 1H-Tetrazole-5-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-17-1 CAPLUS

CN 1H-1,2,4-Triazole-3-acetamide, 2,5-dihydro-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-thioxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

Searched by Barb O'Bryen, STIC 308-4291

RN 223672-18-2 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-19-3 CAPLUS

CN 1,2,4-Thiadiazole-3-acetamide, 5-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-20-6 CAPLUS

CN Carbamic acid, [3-[2-[[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]amino]-2-oxoethyl]-1,2,4-thiadiazol-5-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-21-7 CAPLUS

CN 4-Thiazoleacetamide, 2-[(3-fluorophenyl)amino]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-22-8 CAPLUS

CN 2-Pyridineacetamide, 6-chloro-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-23-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-6-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-24-0 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-methyl-2-propenyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-25-1 CAPLUS

CN 1H-Imidazole-4-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-26-2 CAPLUS

CN 1H-Imidazole-4-acetamide, 1-[(2-chlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-27-3 CAPLUS

CN 1H-Imidazole-4-acetamide, 1-[(3-chlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

Searched by Barb O'Bryen, STIC 308-4291

RN 223672-29-5 CAPLUS

CN 1H-Imidazole-4-acetamide, 1-[(4-chlorophenyl)methyl]-N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-30-8 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-fluorophenyl)methyl]-N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-31-9 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-bromophenyl)methyl]-N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-32-0 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[(4-iodophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-34-2 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[(4-(trifluoromethyl)phenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-36-4 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-naphthalenyl)-, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-38-6 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-fluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-methyl-, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-40-0 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-fluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-42-2 CAPLUS

CN 1H-Tetrazole-5-acetamide, 1-[(4-fluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-44-4 CAPLUS

CN 1H-Tetrazole-5-acetamide, 1-[(3,4-dichlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-46-6 CAPLUS

CN 2H-Tetrazole-5-acetamide, 2-[(4-fluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-47-7 CAPLUS

CN 1H-1,2,4-Triazole-3-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-48-8 CAPLUS

CN 1H-1,2,4-Triazole-3-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-[(phenylmethyl)thio]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-49-9 CAPLUS

CN 4-Thiazoleacetamide, 2-(acetylamino)-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-50-2 CAPLUS

CN 4-Thiazoleacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-2-[(methylsulfonyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-51-3 CAPLUS

CN 4-Thiazoleacetamide, 2-[(aminoiminomethyl)amino]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-52-4 CAPLUS

CN 4-Thiazoleacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-2-(phenylamino)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-53-5 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-[(4-nitrophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-55-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-58-0 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-60-4 CAPLUS

CN 4-Thiazolepropanamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-63-7 CAPLUS

CN 4-Benzothiazolecarboxamide, 2-amino-4,5,6,7-tetrahydro-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

Searched by Barb O'Bryen, STIC 308-4291

RN 223672-65-9 CAPLUS

CN Imidazo[2,1-b]thiazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-66-0 CAPLUS

CN 1H-1,2,4-Triazole-3-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223672-67-1 CAPLUS

CN 4-Thiazoleacetamide, 2,3-dihydro-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-3-(phenylmethyl)-2-thioxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-68-2 CAPLUS

CN 8-Quinolinecarboxamide, 5,6,7,8-tetrahydro-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-69-3 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-70-6 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]aminoethyl]phenyl]-1-[(4-(1-methylethyl)phenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-71-7 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-((1,1'-biphenyl)-4-ylmethyl)-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]aminoethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-72-8 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2-chlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-73-9 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(3-chlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-74-0 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(3,4-dichlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 223672-75-1 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




● 2 HCl

RN 223672-76-2 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-.alpha.-hydroxy-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-77-3 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-methylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-78-4 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[{(2-fluorophenyl)methyl]-N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-79-5 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[{(3-fluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-80-8 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2,4-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-81-9 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2,6-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-82-0 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(3,5-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 223672-83-1 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2,5-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




●2 HCl

RN 223672-84-2 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(3,4-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl


RN 223672-85-3 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[(2R)-2-hydroxy-2-

Searched by Barb O'Bryen, STIC 308-4291

phenylethyl]amino]ethyl]phenyl]-1-[(2,3,6-trifluorophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-86-4 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[(2,4,5-trifluorophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl


Searched by Barb O'Bryen, STIC 308-4291

RN 223672-87-5 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]aminoethyl]phenyl]-1-[(3,4,5-trifluorophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


●2 HCl

RN 223672-88-6 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]aminoethyl]phenyl]-1-[(pentafluorophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 223672-89-7 CAPLUS
 CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]aminoethyl]phenyl]-1-[(3-iodophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-90-0 CAPLUS
 CN 1H-Imidazole-2-acetamide, 1-[(2,6-dichlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]aminoethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




● HCl

RN 223672-91-1 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-cyanophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-92-2 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-1-(2-quinolinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 223672-93-3 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2-chloro-6-fluorophenyl)methyl]-N-[4-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223672-94-4 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2-chloro-4-fluorophenyl)methyl]-N-[4-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223672-95-5 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2,5-dichlorophenyl)methyl]-N-[4-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-96-6 CAPLUS

CN Benzoic acid, 4-[(2-[(4-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl)phenyl]amino]-2-oxoethyl]-1H-imidazol-1-yl)methyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 223672-97-7 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[[4-(1-piperidinylcarbonyl)phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-98-8 CAPLUS

CN 1H-Pyrazole-1-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)
Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




● HCl

RN 223672-99-9 CAPLUS

CN 1H-1,2,4-Triazole-1-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-00-5 CAPLUS

CN 1H-Benzimidazole-1-acetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-01-6 CAPLUS

CN 3-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-02-7 CAPLUS

CN 4-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-03-8 CAPLUS

CN 2-Pyridinepropanamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-04-9 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-phenylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-05-0 CAPLUS

CN 1H-Benzimidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-06-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-07-2 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-08-3 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-09-4 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-10-7 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-11-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[(2R)-2-[(2R)-2-hydroxy-2-phenylethyl]amino]propyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-12-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[(2S)-2-[(2R)-2-hydroxy-2-phenylethyl]amino]propyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-13-0 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[(2S)-2-[(2R)-2-hydroxy-2-phenylethyl]amino]propyl]phenyl-1-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223673-14-1 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-(2-fluorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 223673-15-2 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-(3-fluorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 223673-16-3 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-(4-fluorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 223673-17-4 CAPLUS

CN 2-Quinolineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-18-5 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223673-19-6 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-(3-pyridinyl)ethyl)amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 223673-20-9 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-chlorophenyl)methyl]-N-[4-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-21-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-22-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[(2R)-2-hydroxy-2-phenylethyl]amino]propyl]phenyl-, monohydrochloride (9CI) (CA INDEX Searched by Barb O'Bryen, STIC 308-4291)

NAME)

Absolute stereochemistry.




● HCl

RN 223673-23-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-25-4 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]-2-methylpropyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-26-5 CAPLUS

CN Urea, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-N'-2-pyridinyl-, dihydrochloride (9CI) (CA INDEX NAME)
Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




● 2 HCl

RN 223673-27-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-28-7 CAPLUS

CN 1H-Tetrazole-5-acetamide, 1-[(3,4-dichlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-29-8 CAPLUS

CN 1H-1,2,4-Triazole-5-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-30-1 CAPLUS

CN 2-Pyridineacetamide, 6-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-31-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-32-3 CAPLUS

CN Pyrazineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-33-4 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291

CN 2-Pyrimidineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-58-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-59-4 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-chlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-60-7 CAPLUS

CN 1H-Tetrazole-5-acetamide, 1-[(3,4-dichlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-61-8 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-62-9 CAPLUS

CN 1H-1,2,4-Triazole-5-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-63-0 CAPLUS

CN 2-Pyridineacetamide, 6-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-64-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-65-2 CAPLUS

CN Pyrazineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-66-3 CAPLUS

CN 2-Pyrimidineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 223673-45-8 223673-47-0 223673-48-1

223673-49-2 223673-50-5 223673-51-6

223673-52-7 223673-53-8 223673-56-1


223673-57-2

RL: RCT (Reactant)
(prepn. of amides as antidiabetics)

RN 223673-45-8 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(1H-imidazol-2-ylacetyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-47-0 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(1H-1,2,4-triazol-3-ylacetyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




RN 223673-48-1 CAPLUS
 CN Carbamic acid, [2-[4-[(2-amino-4-thiazolyl)carbonyl]amino]phenyl]ethyl] [(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223673-49-2 CAPLUS
 CN Carbamic acid, [2-[4-[(2-amino-4-thiazolyl)oxoacetyl]amino]phenyl]ethyl] [(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-50-5 CAPLUS
 CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl] [2-[4-[(6-(phenylmethoxy)-2-

Searched by Barb O'Bryen, STIC 308-4291

pyridinyl]acetyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-51-6 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-52-7 CAPLUS

CN 1H-Benzimidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-53-8 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl](phenylmethyl)amino]ethyl]phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-56-1 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(2-pyridinylacetyl)amino]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-57-2 CAPLUS

CN Carbamic acid, [1,1-dimethyl-2-[4-[(2-pyridinylacetyl)amino]phenyl]ethyl][(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 223673-37-8P 223673-38-9P 223673-39-0P

223673-41-4P 223673-44-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of amides as antidiabetics)

RN 223673-37-8 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(2-pyridinylcarbonyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Searched by Barb O'Bryen, STIC 308-4291



RN 223673-38-9 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(8-quinolinylcarbonyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-39-0 CAPLUS

CN Carbamic acid, [2-[4-[[[1-[(2-fluorophenyl)methyl]-1H-imidazol-2-yl]acetyl]amino]phenyl]ethyl][(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-41-4 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl](phenylmethyl)amino]ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-44-7 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl](phenylmethyl)amino]ethyl]phenyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

10

REFERENCE(S):

- (1) Merck & Co Inc; JP 07-10827 A 1995
- (2) Merck & Co Inc; US 5553475 A 1995
- (5) Merck & Co Inc; US 5541197 A 1997 CAPLUS
- (7) Merck & Co Inc; WO 95/29159 A1 1997 CAPLUS
- (10) Takeda Chem Ind Ltd; EP 643050 A1 1996 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1998:535771 CAPLUS

DOCUMENT NUMBER: 129:198012

TITLE: Preparation of phenethanol derivatives and their use as antidiabetic agents

INVENTOR(S): Maruyama, Tatsuya; Onta, Kenichi; Hayakawa, Akihiko; Matsui, Tetsuo

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

Searched by Barb O'Bryen, STIC 308-4291


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10218861	A2	19980818	JP 1997-21870	19970204
OTHER SOURCE(S): MARPAT 129:198012				
GI	For diagram(s), see printed CA Issue.			
AB	The derivs. I [ring B = II, III, IV; X, Y = O, S, NR6; R1 = H, lower alkyl; R2 = H, lower alkyl, NHSO_2Me , NHCOR_3 ; R3 = H, lower alkyl, mono- or di(lower alkylamino), aryl, aralkyl; R4, R5 = H, lower alkyl, amino; R6 = H, lower alkyl, aralkyl] or their salts as $\beta.3$ -adrenoceptor agonists are prep'd. Antidiabetic agents contg. I or thir salts as active ingredients are also claimed. I decreased blood glucose of obese and hyperglycemic kk mice with insulin resistance upon both oral and percutaneous administrations. I also increased insulin secretion in normal rats. Prepn. of some of I was given.			
IT	211636-04-3P 211636-05-4P 211636-06-5P 211636-07-6P 211636-08-7P 211636-09-8P 211636-10-1P 211636-11-2P 211636-13-4P 211636-15-6P 211636-17-8P 211636-18-9P 211636-19-0P 211636-20-3P			
RL	BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(prepn. of antidiabetic phenethanol derivs. as $\beta.3$ -adrenoceptor agonists)			
RN	211636-04-3 CAPLUS			
CN	2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)			



● HCl


RN 211636-05-4 CAPLUS
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-06-5 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-07-6 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-4,6-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-08-7 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 211636-09-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Searched by Barb O'Bryen, STIC 308-4291



● HCl

RN 211636-10-1 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-(3-hydroxyphenyl)ethyl)amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-11-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-(2-hydroxyphenyl)ethyl)amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-13-4 CAPLUS


CN 1H-Benzimidazole-2-acetamide, N-[4-[2-[(2-hydroxy-2-(2-hydroxyphenyl)ethyl)amino]ethyl]phenyl]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-12-3

CMF C25 H26 N4 O3

Searched by Barb O'Bryen, STIC 308-4291




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 211636-15-6 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino)ethyl]phenyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-14-5

CMF C24 H27 N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 211636-17-8 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2-hydroxy-2-(2-hydroxyphenyl)ethyl]amino)ethyl]phenyl]-, hydrochloride trifluoroacetate (2:1:3) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 211636-16-7
 CMF C21 H24 N4 O3 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 211636-18-9 CAPLUS
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 211636-19-0 CAPLUS
 CN 2-Pyridineacetamide, N-[4-[2-[[2-[(3-formylamino)-4-hydroxyphenyl]-2-hydroxyethyl)methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-20-3 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-[(3-(acetylamino)-4-hydroxyphenyl]-2-hydroxyethyl)methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 211635-78-8P 211635-79-9P 211635-80-2P

211635-81-3P 211635-86-8P 211635-87-9P

211635-88-0P 211635-89-1P 211635-92-6P

211635-93-7P 211635-94-8P 211635-95-9P


211635-96-0P 211635-97-1P 211636-00-9P

211636-03-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of antidiabetic phenethanol derivs. as .beta.3-adrenoceptor
agonists)

RN 211635-78-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl]phenylmethyl]amino]ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 211635-79-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[4-
Searched by Barb O'Bryen, STIC 308-4291

(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino]ethyl]phenyl]-4-methyl-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—Ph

RN 211635-80-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(4-
(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino)ethyl]phenyl]-5-methyl-
(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


—CH₂—Ph

RN 211635-81-3 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(4-
(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino)ethyl]phenyl]-6-methyl-
(9CI) (CA INDEX NAME)

RN 211635-86-8 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(4-
(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino)ethyl]phenyl]- (9CI) (CA
INDEX NAME)



RN 211635-87-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

$\text{---CH}_2\text{---Ph}$


RN 211635-88-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[3-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-89-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[2-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-92-6 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 211635-93-7 CAPLUS
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[3-[(methylsulfonyl)amino]-4-(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-94-8 CAPLUS
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[3-nitro-4-(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211635-95-9 CAPLUS
 CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-amino-4-(phenylmethoxy)phenyl]-2-hydroxyethyl] (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-96-0 CAPLUS
 CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(formylamino)-4-(phenylmethoxy)phenyl]-2-hydroxyethyl] (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-97-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-[(4-[(2-hydroxyethyl)amino]benzyl)acetyl]amino)benzyl]acetyl]amino]benzyl]- (9CI) (CA INDEX NAME)




RN 211636-00-9 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2-hydroxy-2-[(2-phenylmethoxy)phenyl]ethyl) (phenylmethyl)amino]ethyl]phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 211636-03-2 CAPLUS

CN Carbamic acid, [2-[4-[(2-amino-4-thiazolyl)acetyl]amino]phenyl]ethyl][2-hydroxy-2-(4-hydroxyphenyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1998:269995 CAPLUS

DOCUMENT NUMBER: 128:303693

TITLE: New Azole Antifungals. 3. Synthesis and Antifungal Activity of 3-Substituted-4(3H)-quinazolinones

AUTHOR(S): Bartrroli, Javier; Turmo, Enric; Alguero, Monica; Boncompte, Eulalia; Vericat, Maria L.; Conte, Lourdes; Ramis, Joaquim; Merlos, Manuel; Garcia-Rafanell, Searched by Barb O'Bryen, STIC 308-4291

CORPORATE SOURCE: Julian; Forn, Javier
 Research Center, J. Uriach Cia. S.A., Barcelona,
 08026, Spain


SOURCE: J. Med. Chem. (1998), 41(11), 1869-1882
 CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB A series of azole antifungal agents featuring a quinazolinone nucleus have been subjected to studies of structure-activity relationships. In general, these compds. displayed higher *in vitro* activities against filamentous fungi and shorter half-lives than the structures described in our preceding paper. The most potent products *in vitro* carried a halogen (or an isostere) at the 7-position of the quinazolinone ring. Using a murine model of systemic candidosis, oral activity was found to be dependent on hydrophobicity, which, in turn, modulated the compd.'s half-life. The 7-Cl deriv., (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one [I, UR-9825], was selected for further testing due to its high *in vitro* activity, low toxicity, good pharmacokinetic profile, and ease of obtention. Compd. I is the (1R,2R) isomer of four possible stereoisomers. The other three isomers were also prep'd. and tested. The enantiomer (1S,2S) and the (1R,2S) epimer were inactive, whereas the (1S,2R) epimer retained some activity. *In vitro*, I was superior to fluconazole, itraconazole, SCH-42427, and TAK-187 and roughly similar to voriconazole and ER-30346. *In vivo*, I was only moderately active in a mouse model of systemic candidosis when administration was limited to the first day. This was attributed to its short half-life in that species ($t_{1/2} = 1$ h po). Protection levels comparable to or higher than those of fluconazole, however, were obsd. in systemic candidosis models in rat and rabbit, where the half-life of the compd. was found to be 6 and 9 h, resp. Finally, I showed excellent protection levels in an immunocompromised rat model of disseminated aspergillosis. The compd. showed low toxicity signs when administered to rats at 250 mg/kg qd or at 100 mg/kg bid during 28 days.


IT 206350-06-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones)


RN 206350-06-3 CAPLUS

CN Benzamide, 4-chloro-N-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-(formylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1992:426440 CAPLUS
 DOCUMENT NUMBER: 117:26440
 TITLE: Triazole antifungals. IV. Synthesis and antifungal activities of 3-acylamino-2-aryl-2-butanol derivatives
 AUTHOR(S): Konosu, Toshiyuki; Tajima, Yawara; Takeda, Noriko; Miyaoka, Takeo; Kasahara, Mayumi; Yasuda, Hiroshi; Oida, Sadao
 CORPORATE SOURCE: Med. Chem. Res. Lab., Sankyo Co., Ltd., Tokyo, 140, Japan
 SOURCE: Chem. Pharm. Bull. (1991), 39(10), 2581-9
 DOCUMENT TYPE: CODEN: CPBTAL; ISSN: 0009-2363
 LANGUAGE: English
 GI



AB New triazoles, e.g., I ($R = 4\text{-Cl, 2,4-Cl}_2, 2,4\text{-F}_2$; $R1 = H, Me$; $R2 = H, CMe_3, Ph$, substituted Ph, 2-furyl, 2-thienyl) were designed and synthesized as potential inhibitors of the fungal cytochrome P 450 14. alpha.-demethylase. In testing for antifungal activity against a mouse systemic *Candida albicans* infection, ($2R,3R$)-3-acylamino-2-aryl-2-butanol derivs. exhibited remarkably high efficacy after oral or parenteral administration. The structure-activity relationships of these amido alcs. were evaluated.


IT 126916-61-8P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. and antifungal activity of)

RN 126916-61-8 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R^*, R^*) $^-$ (9CI) (CA INDEX NAME)
 Searched by Barb O'Bryen, STIC 308-4291

Relative stereochemistry.



IT 138990-07-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 138990-07-5 CAPLUS


CN Benzamide, 4-(acetylamino)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R*,R*)-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 126916-61-8

CMF C21 H21 F2 N5 O3


Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2000 ACS


ACCESSION NUMBER: 1990:631379 CAPLUS

DOCUMENT NUMBER: 113:231379
Searched by Barb O'Bryen, STIC 308-4291

TITLE: Preparation and formulation of (halophenyl)-1H-1,2,4-triazol-1-ylalkanols as medical and agrochemical fungicides
 INVENTOR(S): Oida, Sadao; Tajima, Yawara; Konosu, Toshiyuki; Iwata, Masayuki; Takeda, Noriko; Miyaoka, Takeo; Takeshiba, Hideo; Nakanishi, Toshiro
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 160 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 332387	A1	19890913	EP 1989-302244	19890306
EP 332387	B1	19931124		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8901051	A	19890905	DK 1989-1051	19890303
FI 8901021	A	19890905	FI 1989-1021	19890303
FI 97382	B	19960830		
FI 97382	C	19961210		
NO 8900926	A	19890905	NO 1989-926	19890303
NO 171272	B	19921109		
NO 171272	C	19930217		
JP 02191262	A2	19900727	JP 1989-51336	19890303
HU 53889	A2	19901228	HU 1989-1034	19890303
CN 1036759	A	19891101	CN 1989-101072	19890304
CN 1029962	B	19951011		
AU 8931051	A1	19890907	AU 1989-31051	19890306
AU 622639	B2	19920416		
ZA 8901678	A	19901128	ZA 1989-1678	19890306
AT 97662	E	19931215	AT 1989-302244	19890306
ES 2061975	T3	19941216	ES 1989-302244	19890306
PRIORITY APPLN. INFO.:			JP 1988-51312	19880304
			JP 1988-68681	19880323
			JP 1988-250158	19881004
			JP 1988-261211	19881017
			EP 1989-302244	19890306

OTHER SOURCE(S): MARPAT 113:231379
GI



AB Title compds. I (Ar = (un)substituted Ph; R1 = H, C1-6 alkyl, etc.; R2 = C1-6 alkyl, halo-C1-6-alkyl, (un)substituted Ph, naphthyl, (un)substituted 5-6-membered heterocycl; R3 = H, substituted amino; X = C1-6 alkylene, C2-6 aliph. having 1 or 2 C-C double bonds, C2-6 aliph. having 1 or 2 C-C triple bonds, C3-6 cycloalkylene, etc.; Y = NR5CO, NR5COCH:CH, O2C, O2CCH:CH, SCO, SCOCH:CH, R5 = H, C1-4 alkyl; m, n = 0, 1; YR2 = N3, (un)substituted phthalimido, (un)substituted 1-oxo-2,3-dihydro-2-indolyl)
 Searched by Barb O'Bryen, STIC 308-4291

and acid addn. salts thereof, are prep'd. I are useful as medical and agrochem. fungicides. When used as agrochem. fungicide's, I may be blended with other fungicides and insecticides for a broader fungicidal spectrum and synergistic effect. 4-ClC₆H₄COCl was added to (2R,3R)-3-amino-2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (prepn. given) to give (2R,3R)-I (Ar = 2,4-Cl₂C₆H₃; R₁ = Me; R₃ = H; X_m = O; YR₂ = 4-ClC₆H₄CONH) and converted to the oxalate salt (II). In rice seedlings inoculated with *Rhizoctonia solani*, II at 100 ppm (30 mL/3 pots), gave complete control. Mice inoculated with *Candida albicans* and administered orally II 20 mg/kg, showed 100% survival rate.


IT 126916-61-8P 126918-10-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of, as fungicide)

RN 126916-61-8 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R*,R*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 126918-10-3 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[2-(2,4-dichlorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1990:98544 CAPLUS


DOCUMENT NUMBER: 112:98544

TITLE: Preparation and formulation of 5-hydroxy-8-[1-hydroxy-2-(2-methyl-2-propylamine)ethyl]-2H-1,4-benzoxazin-3-(4H)-ones and analogs containing a quaternary ammonium group as broncholitics
Searched by Barb O'Bryen, STIC 308-4291

INVENTOR(S): Schromm, Kurt; Mentrup, Anton; Renth, Ernst Otto;
 Muacevic, Gojko; Traunecker, Werner
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Fed. Rep.
 Ger.
 SOURCE: Ger. Offen., 30 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3743265	A1	19890629	DE 1987-3743265	19871219
EP 321864	A2	19890628	EP 1988-121011	19881215
EP 321864	A3	19901227		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8809387	A	19900829	ZA 1988-9387	19881215
DK 8807007	A	19890620	DK 1988-7007	19881216
FI 8805811	A	19890620	FI 1988-5811	19881216
NO 8805598	A	19890620	NO 1988-5598	19881216
AU 8827022	A1	19890622	AU 1988-27022	19881216
AU 618302	B2	19911219		
DD 280099	A5	19900627	DD 1988-323312	19881216
SU 1628854	A3	19910215	SU 1988-4613149	19881216
JP 02000239	A2	19900105	JP 1988-320315	19881219
HU 53866	A2	19901228	HU 1988-6491	19881219
HU 207283	B	19930329		
PL 160685	B1	19930430	PL 1988-276549	19881219
US 5223614	A	19930629	US 1990-603585	19901025
PRIORITY APPLN. INFO.:			DE 1987-3743265	19871219
			US 1988-286442	19881219

OTHER SOURCE(S): MARPAT 112:98544
 GI



AB QCH(OH)CHR4NHCR5R6(CH2)nR (Q = Ph group of a broncholytically effective compd., e.g., Q1(R1 = H); R = quaternary ammonium group contg.-alkoxy, -heterocyclyl, -arylalkoxy, etc.; R4 = H, Me, Et; R5,R6 = H, Me; n = 1-5) were prepnd. Thus, Q1COCH(OH)OEt (R1 = Bz) was condensed with 4-(Me2N)C6H4CH2CMe2NH2 and the product treated with NaBH4 to give Q1CH(OH)CH2NHCMe2CH2C6H4NMe2-4 (R1 = Bz) which was condensed with BrCH2CO2Et to give, after hydrolysi and hydrogenolysis, Q1CH(OH)CH2NHCMe2CH2C6H4R2-4 (I) (R1 = H; R2 = N+Me2CH2CO2-)(II). I [R1 = H; R2 = OCH2CH2N+Me2(CH2)3SO2-] gave 50% protection against acetylcholine-induced spasm in guinea pigs after inhalation of a 0.004% aq. soln. An aerosol was prepnd. contg. II 0.1, sorbitan trioleate 0.5, and CFC13 and CF2Cl2 (2:3) 99.4 wt. %.

IT 124955-21-1P 124955-32-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
 Searched by Barb O'Bryen, STIC 308-4291

(prepn. of, as broncholytic)


RN 124955-21-1 CAPLUS

CN Pyridinium, 1-[2-[[4-[2-[[2-(3,4-dihydro-5-hydroxy-3-oxo-2H-1,4-benzoxazin-8-yl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]amino]-2-oxoethyl]-, chloride, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Cl⁻

● HCl

RN 124955-32-4 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291

CN Pyridinium, 1-[[[[[4-[2-[[2-hydroxy-2-[4-hydroxy-3-
[(methoxysulfonyl)amino]phenyl]ethyl]amino]-2-
methylpropyl]phenyl]amino]carbonyl]oxy]methyl]-, chloride,
monohydrochloride (9CI) (CA INDEX NAME)



● Cl⁻

● HCl

FILE 'CAOLD' ENTERED AT 16:00:52 ON 21 AUG 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L6 STR
L8 172 SEA FILE=REGISTRY SSS FUL L6
L10 0 SEA FILE=CAOLD ABB=ON L8 *

=> fil beil; d stat que 115

FILE 'BEILSTEIN' ENTERED AT 16:01:20 ON 21 AUG 2000

COPYRIGHT (c) 2000 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE LAST UPDATED: 6 MAR 2000

FILE COVERS 1779 TO 2000.


*** CAS REGISTRY NUMBERS FOR 4,356,237 SUBSTANCES AVAILABLE ***

*** FILE CONTAINS 7,688,486 SUBSTANCES ***

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

L6

STR



Hy 23

```

VAR G1=C/N
VAR G2=2/3/4
REP G3=(0-1) O
VPA 20-8/9/10 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 14 23
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23

```

```

STEREO ATTRIBUTES: NONE
L15          2 SEA FILE=BEILSTEIN SSS FUL L6

```

```

100.0% PROCESSED 32705 ITERATIONS
SEARCH TIME: 00.00.34


```

2 ANSWERS

=> d ide pre 115 1-2; fil hom

L15 ANSWER 1 OF 2 COPYRIGHT 2000 BEILSTEIN CDS MDL

Beilstein Reg. No. (BRN): 7956379 Beilstein
 Molecular Formula (MF): C20 H18 Cl F2 N5 O3
 Autonom Name (AUN): 4-chloro-N- <2 -(2,4-difluoro-phenyl)-2-hydroxy-1-methyl-3- $<1,2,4$ triazol-1-yl-propyl>-2-formylamino-benzamide
 Beilstein Reference (SO): 6-26
 General Comments (NTE): Stereo compound
 Formula Weight (FW): 449.84
 Lawson Number (LN): 29971; 16524; 16039; 1145



Atom/Bond Notes:

1. CIP Descriptor: R

Preparation:

PRE

Start: BRN=7983052 (1R,2R)-7-chloro-3- <2 -(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- $<1H-1,2,4$ -triazol-1-yl)propyl>quinazolin-4(3H)-one

Reag: 0.1N aq. NaOH

Time: 3 hour(s)

Yield: 25.00 %

Solv: tetrahydrofuran

Ambient Temperature

Reference(s):


1. Bartrolí, Javier; Turmo, Enric; Alugero, Monica; Boncompte, Eulalia; Vericat, Maria L.; et al., J.Med.Chem., 41 <1998> 11, 1869-1882, LA: EN, CODEN: JMCMAR

Same as C APLUS answer # 3

L15 ANSWER 2 OF 2 COPYRIGHT 2000 BEILSTEIN CDS MDL

Beilstein Reg. No. (BRN): 4892790 Beilstein
 Molecular Formula (MF): C21 H21 F2 N5 O3
 Autonom Name (AUN): 4-acetylamino-N- <2 -(2,4-difluoro-phenyl)-2-hydroxy-1-methyl-3- $<1,2,4$ triazol-1-yl-propyl>-benzamide
 Beilstein Reference (SO): 6-26
 General Comments (NTE): Stereo compound; racemate
 Searched by Barb O'Bryen, STIC 308-4291

CAS Reg. No. (RN): 126916-61-8
Beilstein Pref. RN (BPR): 126916-61-8
Formula Weight (FW): 429.43
Lawson Number (LN): 29971; 16524; 16038; 1155



Atom/Bond Notes:

1. CIP Descriptor: R

Fragment Notes:

Additionally represents mirror image

Preparation:

PRE

Start: BRN=4297530 (2R*,3R*)-3-Amino-2-(2,4-difluoropropyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol, BRN=513757 p-acetylaminobenzoyl chloride

Reag: pyridine

Yield: 51.00 %

Temp: 0.0 Cel

Reference(s):

1. Konosu, Toshiyuki; Tajima, Yawara; Takeda, Noriko; Miyaoka, Takeo; Kasahara, Mayumi; et al., Chem.Pharm.Bull., 39 <1991> 10, 2581-2589,
LA: EN, CODEN: CPBTAL

Same as CAPLUS answer #4

FILE 'HOME' ENTERED AT 16:01:34 ON 21 AUG 2000

Best Available Copy

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1992:426440 CAPLUS

DOCUMENT NUMBER: 117:26440

TITLE:

AUTHOR(S):

CORPORATE SOURCE:


SOURCE:

DOCUMENT TYPE:

LANGUAGE:

GI

Triazole antifungals. IV. Synthesis and antifungal activities of 3-acylamino-2-aryl-2-butanol derivatives
 Konosu, Toshiyuki; Tajima, Yawara; Takeda, Noriko;
 Miyaoka, Takeo; Kasahara, Mayumi; Yasuda, Hiroshi;
 Oida, Sadao
 Med. Chem. Res. Lab., Sankyo Co., Ltd., Tokyo, 140,
 Japan
 Chem. Pharm. Bull. (1991), 39(10), 2581-9
 CODEN: CPBTAL; ISSN: 0009-2363
 Journal
 English



AB New triazoles, e.g., I ($R = 4\text{-Cl, 2,4\text{-Cl}_2, 2,4\text{-F}_2}$; $R1 = H, Me$; $R2 = H, CMe_3, Ph$, substituted Ph, 2-furyl, 2-thienyl) were designed and synthesized as potential inhibitors of the fungal cytochrome P 450 14. α -demethylase. In testing for antifungal activity against a mouse systemic *Candida albicans* infection, (2R,3R)-3-acylamino-2-aryl-2-butanol derivs. exhibited remarkably high efficacy after oral or parenteral administration. The structure-activity relationships of these amido alcs. were evaluated.


IT 126916-61-8P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and antifungal activity of)

RN 126916-61-8 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-. (R*.R*)- (9CI) (CA INDEX NAME)
 Searched by Barb O'Bryen, STIC 308-4291

Relative stereochemistry.



IT 138990-07-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 138990-07-5 CAPLUS


CN Benzamide, 4-(acetylamo)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R*,R*)-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 126916-61-8

CMF C21 H21 F2 N5 O3


Relative stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1990:98544 CAPLUS
 DOCUMENT NUMBER: 112:98544
 TITLE: Preparation and formulation of 5-hydroxy-8-[1-hydroxy-2-(2-methyl-2-propylamine)ethyl]-2H-1,4-benzoxazin-3-(4H)-ones and analogs containing a quaternary ammonium group as broncholytics
 INVENTOR(S): Schromm, Kurt; Mentrup, Anton; Renth, Ernst Otto;
 Muacevic, Gojko; Traunecker, Werner
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 30 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3743265	A1	19890629	DE 1987-3743265	19871219
EP 321864	A2	19890628	EP 1988-121011	19881215
EP 321864	A3	19901227		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8809387	A	19900829	ZA 1988-9387	19881215
DK 8807007	A	19890620	DK 1988-7007	19881216
FI 8805811	A	19890620	FI 1988-5811	19881216
NO 8805598	A	19890620	NO 1988-5598	19881216
AU 8827022	A1	19890622	AU 1988-27022	19881216
AU 618302	B2	19911219		
DD 280099	A5	19900627	DD 1988-323312	19881216
SU 1628854	A3	19910215	SU 1988-4613149	19881216
JP 02000239	A2	19900105	JP 1988-320315	19881219
HU 53866	A2	19901228	HU 1988-6491	19881219
HU 207283	B	19930329		
PL 160685	B1	19930430	PL 1988-276549	19881219
US 5223614	A	19930629	US 1990-603585	19901025
PRIORITY APPLN. INFO.:			DE 1987-3743265	19871219
			US 1988-286442	19881219

OTHER SOURCE(S): MARPAT 112:98544
 GI




AB QCH(OH)CHR4NHCR5R6(CH2)nR (Q = Ph group of a broncholytically effective compd., e.g., Q1(R1 = H); R = quaternary ammonium group contg.-alkoxy, -heterocyclyl, -arylalkoxy, etc.; R4 = H, Me, Et; R5,R6 = H, Me; n = 1-5) were prep'd. Thus, Q1COCH(OH)OEt (R1 = Bz) was condensed with 4-(Me2N)C6H4CH2CMe2NH2 and the product treated with NaBH4 to give Q1CH(OH)CH2NHCMe2CH21C6H4NMe2-4 (R1 = Bz) which was condensed with BrCH2CO2Et to give, after hydrolysi and hydrogenolysis, Q1CH(OH)CH2NHCMe2CH2C6H4R2-4 (I) (R1 = H; R2 = N+Me2CH2CO2-) (II). I [R1 = H; R2 = OCH2CH2N+Me2(CH2)3SO2-] gave 50% protection against acetylcholine-induced spasm in guinea pigs after inhalation of a 0.004% aq. soln. An aerosol was prep'd. contg. II 0.1, sorbitan trioleate 0.5, and CFC13 and CF2C12 (2:3) 99.4 wt. %.

IT 124955-21-1P 124955-32-4P


RL: SPN (Synthetic preparation): PREP (Preparation)
 Searched by Barb O'Bryen, STIC 308-4291

RN (prepn. of, as broncholytic)
 124955-21-1 CAPLUS
 CN Pyridinium, 1-[2-[(4-[(2-[(3,4-dihydro-5-hydroxy-3-oxo-2H-1,4-benzoxazin-8-yl)-2-hydroxyethyl]amino)-2-methylpropyl]phenyl]amino]-2-oxoethyl]-, chloride, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● Cl⁻

● HCl

CN Pyridinium, 1-[[[[[4-[2-[[2-hydroxy-2-[4-hydroxy-3-
[(methoxysulfonyl)amino]phenyl]ethyl]amino]-2-
methylpropyl]phenyl]amino]carbonyl]oxy]methyl]-, chloride,
monohydrochloride (9CI) (CA INDEX NAME)




● Cl⁻

● HCl

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1998:535771 CAPLUS
DOCUMENT NUMBER: 129:198012
TITLE: Preparation of phenethanol derivatives and their use
as antidiabetic agents
INVENTOR(S): Maruyama, Tatsuya; Onita, Kenichi; Hayakawa, Akihiko;
Matsui, Tetsuo
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
Searched by Barb O'Bryen, STIC 308-4291


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10218861	A2	19980818	JP 1997-21870	<u>19970204</u>
OTHER SOURCE(S):	MARPAT 129:198012			
GI	For diagram(s), see printed CA Issue.			
AB	The derivs. I [ring B = II, III, IV; X, Y = O, S, NR6; R1 = H, lower alkyl; R2 = H, lower alkyl, NHSO_2Me , NHCOR_3 ; R3 = H, lower alkyl, mono- or di(lower alkylamino), aryl, aralkyl; R4, R5 = H, lower alkyl, amino; R6 = H, lower alkyl, aralkyl] or their salts as $\beta.3$ -adrenoceptor agonists are prep'd. Antidiabetic agents contg. I or their salts as active ingredients are also claimed. I decreased blood glucose of obese and hyperglycemic kk mice with insulin resistance upon both oral and percutaneous administrations. I also increased insulin secretion in normal rats. Prepn. of some of I was given.			
IT	211636-04-3P	211636-05-4P	211636-06-5P	
	211636-07-6P	211636-08-7P	211636-09-8P	
	211636-10-1P	211636-11-2P	211636-13-4P	
	211636-15-6P	211636-17-8P	211636-18-9P	
	211636-19-0P	211636-20-3P		
	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(prepn. of antidiabetic phenethanol derivs. as $\beta.3$ -adrenoceptor agonists)			
RN	211636-04-3 CAPLUS			
CN	2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino]ethyl]phenyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)			



● HCl


RN	211636-05-4 CAPLUS
CN	2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino]ethyl]phenyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-06-5 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-07-6 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-4,6-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-08-7 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 211636-09-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Searched by Barb O'Bryen, STIC 308-4291



● HCl

RN 211636-10-1 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-(3-hydroxyphenyl)ethyl)amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-11-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-(2-hydroxyphenyl)ethyl)amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-13-4 CAPLUS


CN 1H-Benzimidazole-2-acetamide, N-[4-[2-[(2-hydroxy-2-(2-hydroxyphenyl)ethyl)amino]ethyl]phenyl]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-12-3

CMF C25 H26 N4 O3

Searched by Barb O'Bryen, STIC 308-4291




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 211636-15-6 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-(4-hydroxyphenyl)ethyl)methylamino]ethyl]phenyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-14-5

CMF C24 H27 N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 211636-17-8 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2-hydroxy-2-(2-hydroxyphenyl)ethyl)amino]ethyl]phenyl]-, hydrochloride trifluoroacetate (2:1:3) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 211636-16-7
 CMF C21 H24 N4 O3 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 211636-18-9 CAPLUS
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 211636-19-0 CAPLUS
 CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(formylamino)-4-hydroxyphenyl]-2-hydroxyethyl]methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-20-3 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-[3-(acetylamino)-4-hydroxyphenyl]-2-hydroxyethyl)methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 211635-78-8P 211635-79-9P 211635-80-2P

211635-81-3P 211635-86-8P 211635-87-9P

211635-88-0P 211635-89-1P 211635-92-6P

211635-93-7P 211635-94-8P 211635-95-9P


211635-96-0P 211635-97-1P 211636-00-9P

211636-03-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of antidiabetic phenethanol derivs. as .beta.3-adrenoceptor
agonists)

RN 211635-78-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 211635-79-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl)(phenylmethyl)amino]ethyl]phenyl]-3-methyl-
Searched by Barb O'Bryen, STIC 308-4291

(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino]ethyl]phenyl]-4-methyl-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—Ph

RN 211635-80-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(4-(phenylmethoxy)phenyl]ethyl) (phenylmethyl)amino]ethyl]phenyl]-5-methyl-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—Ph


RN 211635-81-3 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(4-(phenylmethoxy)phenyl]ethyl) (phenylmethyl)amino]ethyl]phenyl]-6-methyl-
(9CI) (CA INDEX NAME)



RN 211635-86-8 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(4-(phenylmethoxy)phenyl]ethyl) (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211635-87-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(4-phenylmethoxy)phenyl]ethyl) (phenylmethyl)amino]ethyl]phenyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—Ph


RN 211635-88-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(3-phenylmethoxy)phenyl]ethyl) (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-89-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(4-phenylmethoxy)phenyl]ethyl) (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-92-6 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-hydroxy-2-[(4-phenylmethoxy)phenyl]ethyl) (phenylmethyl)amino]ethyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 211635-93-7 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[3-[(methylsulfonyl)amino]-4-(phenylmethoxy)phenyl]ethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-94-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[3-nitro-4-(phenylmethoxy)phenyl]ethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-95-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-amino-4-(phenylmethoxy)phenyl]-2-hydroxyethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-96-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(formylamino)-4-(phenylmethoxy)phenyl]-2-hydroxyethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-97-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2-[(3-acetyl-4-hydroxy-2-[(2-hydroxyethyl)amino]ethyl)phenyl]amino)ethyl]phenyl]-2-hydroxyethyl](phenylmethyl)amino]ethylphenyl]- (9CI) (CA INDEX NAME)




RN 211636-00-9 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2-hydroxy-2-[(2-phenylmethoxy)ethyl]amino)ethyl]phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 211636-03-2 CAPLUS

CN Carbamic acid, [2-[(2-amino-4-thiazolyl)acetyl]amino]phenyl]ethyl][2-hydroxy-2-(4-hydroxyphenyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1998:269995 CAPLUS

DOCUMENT NUMBER: 128:303693

TITLE: New Azole Antifungals. 3. Synthesis and Antifungal Activity of 3-Substituted-4(3H)-quinazolinones

AUTHOR(S): Bartroli, Javier; Turmo, Enric; Alguero, Monica; Boncompte, Eulalia; Vericat, Maria L.; Conte, Lourdes; Ramis, Joaquim; Merlos, Manuel; Garcia-Rafanell, Searched by Barb O'Bryen, STIC 308-4291



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/529, 096 04/07/00 MARUYAMA

T 07385.0007

HM12/1027

FINNEGAN HENDERSON FARABOW
GARRETT & DUNNER
1300 I STREET NW
WASHINGTON DC 20005-3315

EXAMINER

PATEL, S

ART UNIT

PAPER NUMBER

1624

4

DATE MAILED:

10/27/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.
09/529,096

Applicant

Tatsuya Maruyama et al.

Examiner

Sudhaker Patel

Group Art Unit

1624



Responsive to communication(s) filed on _____

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle* 1035 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 1 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claim

Claim(s) 1-8 is/are pending in the application.

Of the above, claim(s) _____ is/are withdrawn from consideration.

Claim(s) _____ is/are allowed.

Claim(s) _____ is/are rejected.

Claim(s) _____ is/are objected to.

Claims 1-8 are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on _____ is/are objected to by the Examiner.

The proposed drawing correction, filed on _____ is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All Some* None of the CERTIFIED copies of the priority documents have been

received.

received in Application No. (Series Code/Serial Number) _____.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

-- SEE OFFICE ACTION ON THE FOLLOWING PAGES --

Art Unit: 1624

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-3,6-8, drawn to compounds, composition, and method of use for

Formula I where in Z = N; B = 6-membered rings containing at least 1 N and one other heteroatom (0,N,S) e.g. 1,4-, 1,3- diazine, piperazine, morpholine, thiomorpholine etc.

Group II, claim(s) 1-3,6-8, drawn to compounds, composition, and method of use for

Formula I where in Z = N; B= 6-membered rings containing 1 N & 5 carbons, e.g. pyridine, piperidine, quinoline etc..

Group III, claim(s)1-3,6-8, drawn to compounds, composition, and method of use for

Formula I where in Z = N; B = 5-membered rings containing 1N and +0 to 3 heteroatoms (0,S,N) e.g. diazoles, triazoles, tetrazoles, Thiadiazoles, Thiazole etc..

Group IV, claim(s)1-1-4,5,6,7-8, drawn to compounds, composition, and method of use for Formula (I) wherein Z = CH If this group is elected, further restriction(s) will be required..

Group V, claim(s)1-8, drawn to compounds not included in above Groups I-IV.

Art Unit: 1624

In addition to election of one of the above groups, applicants are also required to elect a single species for the group.

2. The inventions listed as **Groups I-V** do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: They have different structures.

3. A telephone call was made to Mr. Hill on 10/24/00 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicants are advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventor ship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventor ship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker Patel whose telephone number is (703) 308 4709. The examiner can normally be reached on Monday thru' Friday from 8:30 AM to 5:00 PM. If attempts to reach

Art Unit: 1624

the examiner by the phone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached at (703) 308 4716.

A facsimile center has been established for Group 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machine are (703) 308-4556 or (703) 305-3592.

Any inquiry of general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308 1235.

sp



Mukund J. Shah

October 25, 2000

Supervisory Patent Examiner

Art Unit 1624